glp 1 and sarcopenia Causes of frailty in people taking GLP1RAs 🧬 New study from #NYCU

Weeks 1 through 4: 0.5 mg once weekly Weeks 5 through 8: 1 mg once weekly Weeks 9 through 12: 2 mg once weekly Weeks 13 through 16: 4 mg once weekly Weeks 17 through 20: 6 mg once weekly Weeks 21 through 24: 8 mg once weekly Weeks 25 and beyond: 10 to 12 mg once weekly (if needed and tolerated) This protocol reaches the 8 mg therapeutic range in approximately 20 weeks

This is why it is important to understand what additional weight management efforts patients pursue in real-world settings after discontinuing semaglutide or tirzepatide, and whether long-term weight changes after discontinuation follow the patterns reported in randomized clinical trials. Hamlet Gasoyan, DS, PhD, MPH According to the researchers, a potential reason for the difference may be that people often continue their treatment journey in other ways

22 One patient had severe acute pancreatitis, and there was one pancreatitis-related death

Cytokine 138 , 155357 (2021)

GLP-1 receptor agonists are transforming weight loss medicine, with semaglutide (Ozempic/Wegovy) delivering 12% weight loss and tirzepatide (Mounjaro/Zepbound) achieving 18% in clinical trials